Results 231 to 240 of about 61,480 (319)

Opportunities of patient‐derived organoids in drug development

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 4, Page 939-944, February 2026.
Various model systems are utilised during drug development starting from basic research, moving to preclinical research and development for clinical applications in order to identify new drugs to improve human health. However, there are characteristics of humans that are not captured by established models.
Antonia Büning, Elena Reckzeh
wiley   +1 more source

Влияние полиморфизмов генов АВСВ1 (rs4148738) и CYP3A4*22 (rs35599367) на терапию блокатором медленных кальциевых каналов амлодипином у больных артериальной гипертензией

open access: green, 2018
Marina Galieva   +7 more
openalex   +1 more source

Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age‐Related Studies in Thai Adults and Cross‐Population Comparisons

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Intrinsic factors such as age and ethnicity influence statin pharmacokinetics (PK) and may increase the risk of muscle‐related adverse events. This study investigated the effect of age on the PK of simvastatin (SV) and its active metabolite, simvastatin acid (SVA), in healthy Thai subjects using an LC–MS/MS assay while accounting for key ...
Thanate Srimatimanon   +11 more
wiley   +1 more source

Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway

open access: yesXenobiotica; the fate of foreign compounds in biological systems, 2015
C. Awortwe   +7 more
semanticscholar   +1 more source

Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women

open access: yesClinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy ...
Andy Sykes   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy